Compounded Wellness Peptides Under Scrutiny: tECRI and ISMP Safety Warning
FDA’s 2026 regulatory shift on compounded peptides highlights major evidence gaps, manufacturing risks, and safety concerns, requiring clinicians to counsel patients and strengthen monitoring.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.